Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT05856578
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Mulberry Twig Alkaloid Tablet — DRUG
    Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
  • Canagliflozin — DRUG
    Canagliflozin 100mg po qd

Study Details

The aim of the study is to investigate the efficacy and safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Canagliflozin for 12 weeks in individuals with type 2 diabetes mellitus

Key Dates

First listed
May 12, 2023
Start date
Mar 15, 2022
Status verified
Jan 2023
Primary completion
May 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Mulberry Twig Alkaloid Tablet
    Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet
  • Active Comparator: Canagliflozin
    Canagliflozin

Primary Outcome Measure

Concentration of FBG, PBG and HbA1c [ Time Frame: 12 weeks ]

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies